A randomised, double-blind, placebo-controlled trial of erythropoietin alfa versus placebo in mechanically ventilated critically ill patients following traumatic injury
Latest Information Update: 01 Jul 2024
Price :
$35 *
At a glance
- Drugs Epoetin alfa (Primary)
- Indications Wounds and injuries
- Focus Therapeutic Use
- Acronyms EPO-TRAUMA
- 09 May 2022 Planned End Date changed from 30 Oct 2024 to 31 Dec 2025.
- 09 May 2022 Planned primary completion date changed from 31 Mar 2025 to 31 Dec 2025.
- 21 Feb 2022 Accrual to date is 20 participants as per Australian New Zealand Clinical Trials Registry record.